關鍵詞： Takeda Amylin 肥胖癥研究
2012年12月29日訊 /生物谷BIOON/ -- Takeda公司取消了與Amylin公司關于肥胖癥研究的合作協議,。該協議總價值達超過美元,，并已進行三年之久。
在協議達成后,，關于肥胖癥的研究進展迅速，Arena的新藥Belviq和Vivus的新藥Qsymia都先后獲得批準,。同時,，Amylin公司被Bristol-Myers Squibb公司收購，而BMY公司在該領域的研究更加領先,。這都預示著肥胖癥領域的良好前景,。
Takeda公司稱,，今后他們將繼續(xù)加強與其他公司在包括肥胖癥研究在內的各領域的合作。（生物谷Bioon.com）
詳細英文報道：
Takeda is writing off its three-year-old $1.1 billion pact with Amylin to develop new obesity drugs. The two companies decided to mutually terminate the pact 17 months after they scrapped a midstage study for their pramlintide/metreleptin combo.
"Having greatly benefited from the Amylin team's collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients," the companies said in a polite joint statement issued on a quiet Christmas Eve.
The biopharma world has changed considerably since Takeda agreed to pay Amylin $75 million upfront to go after the obesity market. Two new drugs, Arena's ($ARNA) Belviq and Vivus's ($VVUS) Qsymia, have since been approved, with Orexigen ($OREX) looking to catch up soon. Amylin was sold to Bristol-Myers Squibb ($BMY), which has other priorities in the pipeline. And there are other experimental drugs in the biotech pipeline whichthat offer considerable promise to dramatically lower weight, a big need in the medical field.
